EichorEICHOR
Study identifier: NCT04336722 Synced from ClinicalTrials.gov · August 08, 2026
● Study status: Completed

Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)

Condition: Biliary Atresia  ·  Sponsor: Albireo, an Ipsen Company

PhasePhase 3
Planned participants254
Who can joinAll sexes, N/A to 111 Days
Healthy volunteersNoCheck eligibility criteria ↓
Where72 locations · 19 countries

Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.

About this study

Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: * A male or female patient with a clinical diagnosis of BA * Age at Kasai HPE ≤90 days * Eligible to start study treatment within 3 weeks post-Kasai HPE Key Exclusion Criteria: * Patients with intractable ascites * Ileal resection surgery * ALT ≥10× upper limit of normal (ULN) at screening * Patients reliant only on total parenteral nutrition, or not able to take study medication orally, at randomization * Acute ascending cholangitis (patients may be randomized after resolution of acute ascending cholangitis) * Choledochal cystic disease * INR \>1.6 (the patient may be treated with Vitamin K intravenously; sample may be redrawn and if INR is ≤1.6 at resampling the patient may be randomized) * Any other conditions or abnormalities, including congenital abnormalities, major cardiac surgery, hepatic, biliary, or GI disease which, in the opinion of the Investigator or Medical Monitor, may compromise the safety of the patient, the integrity of study results, or patient compliance with study requirements * Weight \<3.5kg at randomization

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (72)

Children's Hospital Los AngelesLos Angeles, California, United States
Stanford Children's HealthPalo Alto, California, United States
Rady Children's HospitalSan Diego, California, United States
UCSF Benioff Children's Hospital San FranciscoSan Francisco, California, United States
Children's Hospital ColoradoAurora, Colorado, United States
Nemours/Alfred I. duPont Hospital for ChildrenWilmington, Delaware, United States
Children's National Medical CenterWashington D.C., District of Columbia, United States
University of MiamiMiami, Florida, United States
Children's Healthcare of Atlanta - Emory University School of MedicineAtlanta, Georgia, United States
Ann & Robert H. Lurie Children's HospitalChicago, Illinois, United States
Indiana University school of MedicineIndianapolis, Indiana, United States
Johns Hopkins Children's CenterBaltimore, Maryland, United States

+ 60 more locations — full list on the registry record.

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

Los AngelesPalo AltoSan DiegoSan Francisco

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →